Biopharmaceutical company Lorus Therapeutics has reported positive results from its first-in-human, dose-escalation trial of novel anticancer agent LOR-253.
LOR-253 is a small molecule optimised to induce tumour suppressor Krüppel-like factor 4, causing cancer cell cycle arrest and apoptosis and inhibiting metastasis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In the study, LOR-253 demonstrated a considerable safety profile in addition to encouraging signs of antitumour activity.
Lorus president and CEO Dr Aiping Young said that the results demonstrate that LOR-253 is well tolerated without dose limiting toxicity even at the highest levels.
"More importantly, at higher doses we saw promising dose-related antitumor activity clearly attributable to the drug," she added.
"Safety and pharmacokinetic data suggest the additional opportunity for more frequent dosing of LOR-253 and by combining with other agents we expect to demonstrate even greater antitumor activity in a larger follow-up phase II clinical study."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataA total of 27 patients with advanced solid tumours resistant to multiple standard therapies were enrolled in the study at seven dose levels ranging from 20 to 229mg/m2. The patients had previously failed a median of four prior chemotherapies.
Out of 17 patients evaluable for efficacy, around 41% achieved stable disease by response evaluation criteria in solid tumours (RECIST). The patients suffered from colorectal, lung, appendiceal, liver and uterine cancers.
At higher dose levels of 176mg/m2 and 229mg/m2, around 80% achieved sustained stable disease by RECIST ranging from 5.6 months to eight months, representative of disease control. A non-small cell lung cancer patient at the highest dose level additionally showed non-index tumour shrinkage.
With dose escalation not limited by toxicity, LOR-253 was well tolerated at all dose levels and the most common adverse event was Grade 1 or 2 fatigue seen in three patients.
A follow-up Phase II trial of the regimen in patients with non-small cell lung cancer as the first indication for further development is currently being designed by the company.
